-
Biogen Idec and partner Elan had to pull their multiple sclerosis drug Tysabri after patients in clinical trials came down with a rare viral disorder that can lead to brain damage or death.
FORBES: Genentech's Next Act
-
Verizon is a stronger partner, and its management team has proved itself able to successfully pull off big mergers.
FORBES: Call It Quits, Qwest
-
In a research note, Scott Sweet, IPO Boutique senior managing partner, said there hasn't been an IPO that has exuded such a pull on investors since Google Inc.
WSJ: IPO Analysts Warn of Longer-Term Facebook Risks